Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 04:53 ET | Source: Exact Therapeutics AS

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026...
December 23, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu
December 18, 2025 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
December 15, 2025 09:00 ET | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
December 02, 2025 09:00 ET | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for...
November 12, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million...
November 12, 2025 12:00 ET | Source: BetaGlue Therapeutics SpA

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLPDAC)
November 04, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...
October 24, 2025 11:45 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC
September 26, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...